About My Health Careers Internship MedBlogs Contact us

Experimental Drug Active in Platinum-Resistant Ovarian Cancers

by Sheela Philomena on April 7, 2013 at 11:29 AM
Font : A-A+

 Experimental Drug Active in Platinum-Resistant Ovarian Cancers

DMUC5754A - a novel experimental drug was found to show promising results in women with platinum-resistant ovarian cancers, find clinical trials.

"If the activity of this drug is confirmed in additional trials, this will represent a novel type of therapy for ovarian cancer, with effectiveness in platinum-resistant ovarian cancer, which is the hardest type of ovarian cancer to treat," said Joyce F. Liu, M.D., M.P.H., an instructor in medicine at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Mass. "This would represent a real step forward in finding new, effective treatments for advanced ovarian cancer."


According to Liu, ovarian cancer is the leading cause of death from gynecologic cancers in the United States. It affects more than 22,000 women per year and results in about 16,000 deaths per year. One of the biggest challenges in treating ovarian cancer is the development of platinum resistance, where the cancer cells stop responding to platinum chemotherapy, one of the most effective drugs in treating this cancer. Standard chemotherapies have limited effect against these platinum-resistant ovarian cancers, and women whose cancers have become platinum-resistant inevitably have disease progression.

"The drug we tested in this clinical trial, DMUC5754A, is from a new class of drugs called antibody-drug conjugates," Liu said. "This drug consists of an antibody and a potent toxin joined by a cleavable linker. The antibody identifies a protein, MUC16, which is highly expressed in ovarian cancers, and targets the toxin to kill the cancer cells."

Unlike other cancer treatments, the antibody-drug conjugate releases the toxin with relative selectivity to the MUC16-positive cancer cells. This allows delivery of drugs that would otherwise be too toxic for treatment, according to Liu.

She and her colleagues evaluated the safety, pharmacokinetics and pharmacodynamic activity of DMUC5754A in 44 patients with advanced, recurrent, platinum-resistant ovarian cancer. Researchers reported one complete response and four partial responses. All five of these confirmed responses occurred at the 2.4-mg/kg dose and in patients with high expression levels of MUC16 in their cancer cells.

During the study, two dose-limiting toxicities occurred: one grade 4 neutropenia and one grade 4 uric acid increase, which occurred at the maximum administered dose of 3.2 mg/kg. Grade 3 adverse events included fatigue in 9 percent of patients and neutropenia in 9 percent of patients. Fatigue was the most common adverse event at all dose levels and occurred in 57 percent of patients. Other commonly reported adverse events were nausea, vomiting, decreased appetite, diarrhea and peripheral neuropathy.

Liu and her colleagues next plan to evaluate this drug in comparison with standard chemotherapy.

DMUC5754A is being developed by Genentech, a member of the Roche Group.

Source: Newswise

News A-Z
News Category
What's New on Medindia
Turmeric: Magic Ingredient to Keep you Healthy in Winter
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Ovarian Cancer Signature Drug Toxicity Cancer Ovarian Pain Premature Ovarian Failure 

Recommended Reading
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of ....
Mayo Clinic Researchers Identify New Gene That Increases Risk of Ovarian Cancer
A new gene, known as HNF1B, which increases a woman's risk of developing ovarian cancer has been ......
Source of Ovarian Stem-like Cells Prone to Giving Rise to Ovarian Cancer Uncovered By Scientists
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has discovered cells with ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Ovarian Cancer
Ovarian cancer affects both the ovaries and is referred to as the ''silent killer'' as the symptoms ...
Ovarian Pain
Ovarian pain is caused due to various conditions like ovarian cysts, ovarian tumors, endometriosis, ...
Premature Ovarian Failure
Premature menopause is ovarian failure which occurs 2 SD in years before a mean menopausal age and p...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use